Contract-Resource-Outsourcing-IndustryNews

  1. Phase III Study Showed Lucentis Improved Vision In Patients With Branch Retinal Vein Occlusion 7/7/2009
    Genentech, Inc. announced recently that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in patients with macular edema due to branch retinal vein occlusion.
  2. Novasep Acquires Bioprocess Development Specialist And Contract Manufacturer Henogen 7/7/2009
    Novasep, a leading producer of active pharmaceutical ingredients (APIs) and purification technologies for the life science industries, announces recently the acquisition of Henogen, a contract manufacturing organization (CMO) offering bioprocess development and manufacturing services from the cell bank to the supply of clinical products.
  3. Biologics Dominate The Autoimmune Market But Small Molecules Still Have Some Fight Left, Says Cutting Edge Information 7/1/2009
    Biological drugs are the big winners in the market for autoimmune disorders.
  4. Azopharma Completion Of New Cytotoxic Manufacturing Suites For Clinical Trial Materials 6/23/2009
    Azopharma Product Development Group, is pleased to announce the completed expansion of its cGMP cytotoxic and highly-potent compound facilities at its South Florida-Hollywood location.
  5. AstraZeneca And Abbott Submit New Drug Application To The FDA For The Approval Of CERTRIAD For The Treatment Of Mixed Dyslipidemia 6/5/2009
    AstraZeneca and Abbott announced recently that the companies have submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational compound for the treatment of mixed dyslipidemia, a combination of two or more lipid abnormalities including high LDL cholesterol (the “bad” cholesterol), high triglycerides and low HDL-cholesterol (the “good” cholesterol).
  6. Azopharma Product Development Group Appoints New CFO 6/3/2009
    Azopharma Product Development Group, a leading provider of product development services to the pharmaceutical, biotechnology and medical device industry, is pleased to announce Daniel Cammarata, CPA has joined the company as its Chief Financial Officer.
  7. SAFC And Cherokee Pharmaceuticals Pool Expertise And Resources With Strategic Partnership For U.S. Market 6/2/2009
    SAFC® (www.safcglobal.com), a member of the Sigma-Aldrich® group (NASDAQ: SIAL) and Cherokee Pharmaceuticals TM (www.cherokee-pharma.com), a PRWT Services, Inc. company and minority owned business, today announced an exclusive strategic partnership that encompasses the sourcing, analytical testing, warehousing, packaging and distribution of large-scale raw materials for pharmaceutical manufacturing meeting cGMP quality standards.
  8. Cornerstone Pharmaceuticals Initiates Phase I/II Combination Therapy Clinical Trial Of CPI-613 For Treatment Of Pancreatic Cancer 5/28/2009
    Cornerstone Pharmaceuticals, Inc., a privately-held pharmaceutical company, announced today that it has begun a phase I/II clinical trial of CPI-613, the initial candidate to emerge from the company's Altered Energy Metabolism Directed technology platform.
  9. Dr. Reddy's Receives Approval For Three INDs And Announces Reorganization Of Its Drug Discovery Operations 5/25/2009
    Dr. Reddy's announced that the first human subjects were successfully dosed in a phase I study with DRL 17822, a selective inhibitor of CETP, for the treatment of dyslipidemia, atherosclerosis and associated cardiovascular diseases.
  10. Genentech And Biogen Idec Submit Applications To The FDA For Rituxan For Most Common Type Of Adult Leukemia 5/21/2009
    Genentech, Inc. and Biogen Idec recently announced that the companies submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Rituxan (rituximab) plus standard chemotherapy for people with previously untreated or treated chronic lymphocytic leukemia (CLL).